Clinical Scorecard: Investigating the Structure-Activity Relationships of Synthetic Cathinones: A Comprehensive Study of α-PiHP Analogues Through In Silico, In Vitro, and In Vivo Approaches
At a Glance
Category
Detail
Condition
Synthetic Cathinones (SCs)
Key Mechanisms
Modulation of monoamine signalling through transporter blocking and monoamine release.
Target Population
Individuals using New Psychoactive Substances (NPS).
Care Setting
Research and forensic toxicology.
Key Highlights
α-PiHP is a potent DAT inhibitor with high abuse potential.
Reported effects of α-PiHP include euphoria, tachycardia, and paranoia.
Emerging analogues of α-PiHP have been identified with varying structural modifications.
In vivo studies indicate robust psychostimulant effects similar to cocaine and methamphetamine.
α-PiHP was placed in Schedule II on the list of Psychotropic Substances in 2023.
Guideline-Based Recommendations
Diagnosis
Identification of SCs through forensic toxicology.
Management
Monitoring and risk assessment of emerging SCs.
Monitoring & Follow-up
Surveillance of NPS trends and associated health effects.
Risks
Potential for severe adverse effects including tachycardia and hyperthermia.
Patient & Prescribing Data
Users of synthetic cathinones and NPS.
Limited data on long-term effects and toxicity.
Clinical Best Practices
Conduct thorough risk assessments for emerging SCs.
Utilize in vitro and in vivo studies to understand pharmacological profiles.
by Martalu D. Pazos, Guillermo García-Díez, David Pubill, Xavier Berzosa, Roger Estrada-Tejedor, Jorge Camarasa, Elena Escubedo, Raúl López-Arnau, Núria Nadal-Gratacós
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
